SCHEMBL10135674

SCHEMBL10135674

COc1ccc(Cc2cc(I)sc2C)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC5A2 P31639 1/20 0.48
LTA4H P09960 1/20 0.44
ALDH1A1 P00352 2/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
POLB P06746 1/20 0.41
APP P05067 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MPI P34949 1/20 0.40
APOBEC3G Q9HC16 1/20 0.40
COMT P21964 1/20 0.39
CNR2 P34972 1/20 0.39
IDO1 P14902 1/20 0.39
ALOX5 P09917 1/20 0.39
IDH1 O75874 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SLC5A1 P13866 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL460839 0.81 SLC5A2 (0.48) SLC5A2LTA4HALDH1A1LMNAHPGD
SCHEMBL461010 0.80 SLC5A2 (0.47) SLC5A2ALOX5IDH1MEN1KMT2A
SCHEMBL460784 0.79 PREP (0.39) SLC5A2ALDH1A1LMNAHPGDPOLB
SCHEMBL3771475 0.72 APP (0.49) SLC5A2LTA4HLMNAAPPCNR2
SCHEMBL7846076 0.70 LTA4H (0.52) LTA4HCNR2IDO1SLC5A1
SCHEMBL17929395 0.70 CNR2 (0.44) SLC5A2LTA4HAPPCNR2SLC5A1
SCHEMBL27884 0.70 LTA4H (0.81) LTA4HALDH1A1LMNAIDO1
SCHEMBL25986524 0.70 LTA4H (0.81) LTA4HALDH1A1LMNAIDO1
SCHEMBL1425001 0.70 LTA4H (0.81) LTA4HALDH1A1LMNAIDO1
SCHEMBL6545565 0.69 LTA4H (0.60) SLC5A2LTA4HAPPIDO1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9006187-B2 Thiophene derivative as SGLT2 inhibitor and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2015-04-14 US disclosed
US-9006187-B2 Thiophene derivative as SGLT2 inhibitor and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2015-04-14 US disclosed
US-9006187-B2 Thiophene derivative as SGLT2 inhibitor and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2015-04-14 US disclosed
US-20130172278-A1 NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2013-07-04 US disclosed
US-20130172278-A1 NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2013-07-04 US disclosed
US-20130172278-A1 NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2013-07-04 US disclosed
WO-2012033390-A2 NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172278-A1 NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME SLC5A2, SLC5A1, SLC2A2 SLC5A2 1/4885LTA4H 2470/4885ALDH1A1 1762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.